| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.26B | 9.38 | 67 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 692.99M | 4.09 | 10.76 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 932.87M | 2.35 | -1.84 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 630.68M | 8.04 | -2.62 | -117.82% | 0.18 | |||
| IMNMImmunome, Inc. | 2.22B | 20.14 | -4.03 | -35.5% | -23.01% | -84.4% | 0.03 | |
| NKTRNektar Therapeutics | 744.1M | 36.58 | -4.21 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IBRXImmunityBio, Inc. | 2.78B | 2.82 | -4.55 | 22.71% | -422.28% | |||
| CRVSCorvus Pharmaceuticals, Inc. | 485.43M | 6.50 | -6.37 | -21.01% | 0.03 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 3.77M | 18.45M | 31.25M | 34.76M | 172.83M | 54M | 155.84M |
| Revenue Growth % | - | 3.89% | 0.69% | 0.11% | 3.97% | -0.69% | 1.89% |
| Cost of Goods Sold | 33.97M | 40.09M | 67.08M | 87.57M | 106.78M | 118.66M | 0 |
| COGS % of Revenue | 9.01% | 2.17% | 2.15% | 2.52% | 0.62% | 2.2% | - |
| Gross Profit | -30.2M | -21.64M | -35.83M | -52.81M | 66.05M | -64.67M | 155.84M |
| Gross Margin % | -8.01% | -1.17% | -1.15% | -1.52% | 0.38% | -1.2% | 1% |
| Gross Profit Growth % | - | 0.28% | -0.66% | -0.47% | 2.25% | -1.98% | 3.41% |
| Operating Expenses | 38.18M | 51.46M | 100.97M | 121.05M | 142.88M | 155.72M | 194.45M |
| OpEx % of Revenue | 10.13% | 2.79% | 3.23% | 3.48% | 0.83% | 2.88% | 1.25% |
| Selling, General & Admin | 7.67M | 11.76M | 34.19M | 33.81M | 36.12M | 38.2M | 46.45M |
| SG&A % of Revenue | 2.03% | 0.64% | 1.09% | 0.97% | 0.21% | 0.71% | 0.3% |
| Research & Development | 33.97M | 40.09M | 67.08M | 87.57M | 106.78M | 118.66M | 148.08M |
| R&D % of Revenue | 9.01% | 2.17% | 2.15% | 2.52% | 0.62% | 2.2% | 0.95% |
| Other Operating Expenses | -3.46M | -385K | -303K | -332K | -26K | -1.14M | -78K |
| Operating Income | -34.41M | -33.01M | -69.72M | -86.29M | 29.95M | -101.72M | -38.62M |
| Operating Margin % | -9.13% | -1.79% | -2.23% | -2.48% | 0.17% | -1.88% | -0.25% |
| Operating Income Growth % | - | 0.04% | -1.11% | -0.24% | 1.35% | -4.4% | 0.62% |
| EBITDA | -32.16M | -29.17M | -65.59M | -80.82M | 36.8M | -94.49M | -26.39M |
| EBITDA Margin % | -8.53% | -1.58% | -2.1% | -2.33% | 0.21% | -1.75% | -0.17% |
| EBITDA Growth % | - | 0.09% | -1.25% | -0.23% | 1.46% | -3.57% | 0.72% |
| D&A (Non-Cash Add-back) | 2.25M | 3.85M | 4.12M | 5.47M | 6.84M | 7.23M | 12.22M |
| EBIT | -32.34M | -32.32M | -211.55M | -92.77M | 43.07M | -96.16M | 22.23M |
| Net Interest Income | 491K | 620K | 561K | -433K | 1.44M | 13.01M | 24.11M |
| Interest Income | 507K | 790K | 850K | 133K | 2.48M | 13.85M | 25M |
| Interest Expense | 16K | 170K | 289K | 566K | 1.04M | 831K | 886K |
| Other Income/Expense | 2.05M | 526K | -142.13M | -7.04M | 12.08M | 4.73M | 59.96M |
| Pretax Income | -32.35M | -32.49M | -229.62M | -93.33M | 42.04M | -96.99M | 21.35M |
| Pretax Margin % | -8.58% | -1.76% | -7.35% | -2.68% | 0.24% | -1.8% | 0.14% |
| Income Tax | 0 | 0 | -268K | 0 | 4.55M | 0 | 6.13M |
| Effective Tax Rate % | 0.97% | 0.98% | 1% | 1.02% | 0.89% | 1% | 0.71% |
| Net Income | -31.44M | -31.74M | -229.35M | -95.06M | 37.51M | -96.99M | 15.22M |
| Net Margin % | -8.34% | -1.72% | -7.34% | -2.73% | 0.22% | -1.8% | 0.1% |
| Net Income Growth % | - | -0.01% | -6.23% | 0.59% | 1.39% | -3.59% | 1.16% |
| Net Income (Continuing) | -32.35M | -32.49M | -211.84M | -93.33M | 37.51M | -96.99M | 15.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1.24M | 1.02M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.50 | -0.50 | -4.78 | -1.51 | 0.54 | -1.20 | 0.14 |
| EPS Growth % | - | 0% | -8.56% | 0.68% | 1.36% | -3.22% | 1.12% |
| EPS (Basic) | -0.50 | -0.50 | -4.78 | -1.51 | 0.55 | -1.20 | 0.14 |
| Diluted Shares Outstanding | 62.91M | 62.91M | 48M | 62.91M | 68.82M | 80.55M | 106.8M |
| Basic Shares Outstanding | 62.91M | 62.91M | 48M | 62.91M | 67.22M | 80.55M | 108.7M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 55.29M | 124M | 238.99M | 152.21M | 377.15M | 449.37M | 629.55M |
| Cash & Short-Term Investments | 52.47M | 119.38M | 231.98M | 145.12M | 362.2M | 425.89M | 604.45M |
| Cash Only | 39.37M | 103.35M | 207.53M | 132.99M | 148.52M | 218.47M | 236.75M |
| Short-Term Investments | 13.1M | 16.02M | 24.45M | 12.12M | 213.69M | 207.42M | 367.7M |
| Accounts Receivable | 1.82M | 2.72M | 2.92M | 2.36M | 1.11M | 5.74M | 6.75M |
| Days Sales Outstanding | 176.01 | 53.87 | 34.14 | 24.77 | 2.35 | 38.78 | 15.8 |
| Inventory | 0 | 1.24M | 3.3M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 11.25 | 17.97 | - | - | - | - |
| Other Current Assets | 1M | 665K | 1.7M | 950K | 13.84M | 7.12M | 6.31M |
| Total Non-Current Assets | 6.03M | 10.28M | 15.65M | 22.44M | 30.67M | 60.59M | 66.59M |
| Property, Plant & Equipment | 4.01M | 8.01M | 14.02M | 20.49M | 26.49M | 57.05M | 63.71M |
| Fixed Asset Turnover | 0.94x | 2.30x | 2.23x | 1.70x | 6.52x | 0.95x | 2.45x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.04M | 1.01M | 913K | 1.31M | 1.63M | 1.52M | 1.63M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 984K | 1.26M | 726K | 636K | 2.54M | 2.02M | 1.25M |
| Total Assets | 61.32M | 134.28M | 254.65M | 174.65M | 407.82M | 509.96M | 696.15M |
| Asset Turnover | 0.06x | 0.14x | 0.12x | 0.20x | 0.42x | 0.11x | 0.22x |
| Asset Growth % | - | 1.19% | 0.9% | -0.31% | 1.34% | 0.25% | 0.37% |
| Total Current Liabilities | 26.84M | 69.3M | 60.61M | 95.15M | 106.45M | 156.55M | 67.99M |
| Accounts Payable | 4.8M | 4.87M | 2.55M | 3.01M | 4.03M | 7.67M | 10.11M |
| Days Payables Outstanding | 51.6 | 44.3 | 13.9 | 12.54 | 13.76 | 23.58 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 888K | 65K | 212K | 28.04M | 17.88M | 20.48M | 4.77M |
| Current Ratio | 2.06x | 1.79x | 3.94x | 1.60x | 3.54x | 2.87x | 9.26x |
| Quick Ratio | 2.06x | 1.77x | 3.89x | 1.60x | 3.54x | 2.87x | 9.26x |
| Cash Conversion Cycle | - | 20.82 | 38.21 | - | - | - | - |
| Total Non-Current Liabilities | 43.65M | 105.82M | 89.78M | 55.44M | 88.2M | 128.33M | 53.32M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 1.82M | 4.31M | 7.14M | 12.4M | 12.8M | 13.35M |
| Deferred Tax Liabilities | 0 | 0 | -4.31M | 0 | 0 | 0 | 5.8M |
| Other Non-Current Liabilities | 220K | 103.99M | 0 | 48.29M | 42K | 115.53M | 0 |
| Total Liabilities | 70.49M | 175.11M | 150.39M | 150.58M | 194.66M | 284.88M | 121.3M |
| Total Debt | 0 | 3.23M | 6.19M | 9.85M | 14.56M | 15.4M | 16.2M |
| Net Debt | -39.37M | -100.12M | -201.34M | -123.14M | -133.96M | -203.07M | -220.54M |
| Debt / Equity | - | - | 0.06x | 0.41x | 0.07x | 0.07x | 0.03x |
| Debt / EBITDA | - | - | - | - | 0.40x | - | - |
| Net Debt / EBITDA | - | - | - | - | -3.64x | - | - |
| Interest Coverage | -2150.56x | -194.19x | -241.23x | -152.46x | 28.86x | -122.41x | -43.58x |
| Total Equity | -9.17M | -40.84M | 104.26M | 24.06M | 213.16M | 225.08M | 574.84M |
| Equity Growth % | - | -3.45% | 3.55% | -0.77% | 7.86% | 0.06% | 1.55% |
| Book Value per Share | -0.15 | -0.65 | 2.17 | 0.38 | 3.10 | 2.79 | 5.38 |
| Total Shareholders' Equity | -10.41M | -41.85M | 104.26M | 24.06M | 213.16M | 225.08M | 574.84M |
| Common Stock | 1.16M | 1.16M | 629K | 629K | 767K | 847K | 1.22M |
| Retained Earnings | -201.62M | -233.19M | -462.25M | -537.81M | -500.3M | -597.29M | -589.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -741K | -770K | -7.46M | -3.94M | -1.48M | -1.64M | 1.03M |
| Minority Interest | 1.24M | 1.02M | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 20.68M | 70.97M | -85.61M | -81.78M | 100.13M | 18.23M | -158.03M |
| Operating CF Margin % | 5.49% | 3.85% | -2.74% | -2.35% | 0.58% | 0.34% | -1.01% |
| Operating CF Growth % | - | 2.43% | -2.21% | 0.04% | 2.22% | -0.82% | -9.67% |
| Net Income | -32.35M | -32.49M | -229.62M | -93.33M | 37.51M | -94.65M | 15.22M |
| Depreciation & Amortization | 2.18M | 3.86M | 4.42M | 5.26M | 6.97M | 7.23M | 12.22M |
| Stock-Based Compensation | 1.48M | 852K | 22.95M | 26.4M | 22.57M | 20.7M | 17.64M |
| Deferred Taxes | 491K | 623K | -3.96M | 11.15M | 4.52M | 0 | 6.13M |
| Other Non-Cash Items | -271K | 1.24M | 145.87M | 433K | -8.7M | 3.31M | -45.37M |
| Working Capital Changes | 49.16M | 96.88M | -25.28M | -31.7M | 37.26M | 81.63M | -163.88M |
| Change in Receivables | -175K | -563K | -294K | 569K | -429K | -2.98M | -1.76M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -84.24M | 0 |
| Change in Payables | 43.73M | 98.94M | -23.39M | -31.78M | 45.56M | 84.24M | 0 |
| Cash from Investing | -13.51M | -5.06M | -15.95M | 7.49M | -209.79M | -31.39M | -152.39M |
| Capital Expenditures | -507K | -2.23M | -7.52M | -5.66M | -6.21M | -30.8M | -16.27M |
| CapEx % of Revenue | 0.13% | 0.12% | 0.24% | 0.16% | 0.04% | 0.57% | 0.1% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 94K | 6K | -104K | -551K | 199.96M | -8K | -206K |
| Cash from Financing | 23.65M | -1.86M | 207.88M | -2.61M | 123.71M | 84.52M | 319.68M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -7.94M | 0 | -7.93M | -2.04M | -21.31M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | 20.18M | 68.73M | -93.13M | -87.44M | 93.92M | -12.73M | -174.51M |
| FCF Margin % | 5.35% | 3.73% | -2.98% | -2.52% | 0.54% | -0.24% | -1.12% |
| FCF Growth % | - | 2.41% | -2.36% | 0.06% | 2.07% | -1.14% | -12.71% |
| FCF per Share | 0.32 | 1.09 | -1.94 | -1.39 | 1.36 | -0.16 | -1.63 |
| FCF Conversion (FCF/Net Income) | -0.66x | -2.24x | 0.37x | 0.86x | 2.67x | -0.19x | -10.38x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -723.26% | -148.16% | 31.63% | -44.26% | 3.8% |
| Return on Invested Capital (ROIC) | - | - | - | - | 28.36% | -150.75% | -15.39% |
| Gross Margin | -801.09% | -117.31% | -114.65% | -151.92% | 38.22% | -119.76% | 100% |
| Net Margin | -834.06% | -172.05% | -733.84% | -273.45% | 21.71% | -179.63% | 9.77% |
| Debt / Equity | - | - | 0.06x | 0.41x | 0.07x | 0.07x | 0.03x |
| Interest Coverage | -2150.56x | -194.19x | -241.23x | -152.46x | 28.86x | -122.41x | -43.58x |
| FCF Conversion | -0.66x | -2.24x | 0.37x | 0.86x | 2.67x | -0.19x | -10.38x |
| Revenue Growth | - | 389.36% | 69.4% | 11.23% | 397.17% | -68.76% | 188.6% |
Immatics N.V. (IMTX) has a price-to-earnings (P/E) ratio of 67.0x. This suggests investors expect higher future growth.
Immatics N.V. (IMTX) reported $84.8M in revenue for fiscal year 2024. This represents a 2148% increase from $3.8M in 2018.
Immatics N.V. (IMTX) grew revenue by 188.6% over the past year. This is strong growth.
Immatics N.V. (IMTX) reported a net loss of $115.9M for fiscal year 2024.
Immatics N.V. (IMTX) has a return on equity (ROE) of 3.8%. This is below average, suggesting room for improvement.
Immatics N.V. (IMTX) had negative free cash flow of $183.9M in fiscal year 2024, likely due to heavy capital investments.